Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sally Tran

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Alimentary Pharmacology & Therapeutics|February 27, 2025
Differential Characteristics and Survival Outcomes of Patients With Cirrhosis According to Underlying Liver AetiologyYu Shi, Nicholas Chien, Ashley Fong, et al.
Hepatology (Baltimore, Md.)|March 11, 2021
Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine PracticeHidenori Toyoda, Jennifer Leong, Charles Landis, et al.
Journal of Gastroenterology and Hepatology|August 26, 2020
High hepatitis C virus cure rates with approved interferon-free direct-acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3bFanpu Ji, Jie Li, Li Liu, et al.
Hepatology International|August 30, 2019
Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C ConsortiumChung-Feng Huang, Etsuko Iio, Dae Won Jun, et al.
Hepatology (Baltimore, Md.)|May 15, 2023
Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phaseDaniel Q Huang, Andrew Tran, Ming-Lun Yeh, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 29, 2019
Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice ImplicationEiichi Ogawa, Hidenori Toyoda, Etsuko Iio, et al.
Hepatology (Baltimore, Md.)|June 25, 2025
Type 2 diabetes mellitus as an independent predictor of significant fibrosis in treatment-naïve chronic hepatitis B patients with concurrent hepatic steatosisJie Li, Liang Xu, Fajuan Rui, et al.
Hepatology International|June 5, 2023
Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C studyYu Jun Wong, Sally Tran, Chung-Feng Huang, et al.
The American Journal of Gastroenterology|June 14, 2026
Higher incidence of hepatocellular carcinoma in suppressed hepatitis B cirrhosis compared to cured hepatitis C cirrhosisJiyoon Park, Sally Tran, Eiichi Ogawa, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 22, 2026
Long-Term Mortality Following Hepatitis C Cure in a Real-World Multinational CohortFanpu Ji, Sally Tran, Hidenori Toyoda, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Alimentary Pharmacology & Therapeutics|February 27, 2025
Differential Characteristics and Survival Outcomes of Patients With Cirrhosis According to Underlying Liver AetiologyYu Shi, Nicholas Chien, Ashley Fong, et al.
Hepatology (Baltimore, Md.)|March 11, 2021
Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine PracticeHidenori Toyoda, Jennifer Leong, Charles Landis, et al.
Journal of Gastroenterology and Hepatology|August 26, 2020
High hepatitis C virus cure rates with approved interferon-free direct-acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3bFanpu Ji, Jie Li, Li Liu, et al.
Hepatology International|August 30, 2019
Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C ConsortiumChung-Feng Huang, Etsuko Iio, Dae Won Jun, et al.
Hepatology (Baltimore, Md.)|May 15, 2023
Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phaseDaniel Q Huang, Andrew Tran, Ming-Lun Yeh, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 29, 2019
Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice ImplicationEiichi Ogawa, Hidenori Toyoda, Etsuko Iio, et al.
Hepatology (Baltimore, Md.)|June 25, 2025
Type 2 diabetes mellitus as an independent predictor of significant fibrosis in treatment-naïve chronic hepatitis B patients with concurrent hepatic steatosisJie Li, Liang Xu, Fajuan Rui, et al.
Hepatology International|June 5, 2023
Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C studyYu Jun Wong, Sally Tran, Chung-Feng Huang, et al.
The American Journal of Gastroenterology|June 14, 2026
Higher incidence of hepatocellular carcinoma in suppressed hepatitis B cirrhosis compared to cured hepatitis C cirrhosisJiyoon Park, Sally Tran, Eiichi Ogawa, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 22, 2026
Long-Term Mortality Following Hepatitis C Cure in a Real-World Multinational CohortFanpu Ji, Sally Tran, Hidenori Toyoda, et al.
Pageof 3